Tegaserod meta-analysis: Global relief of IBS symptoms, no increase in abdominal surgery
Tegaserod, an investigational serotonin receptor agonist, provides global relief of the symptoms of constipation-predominant irritable bowel syndrome (IBS) with an acceptable incidence of adverse events, according to the results of meta-analysis of four phase III trials presented at Digestive Disease Week in San Francisco.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
